Prevention and treatment of retroviral disease
AssigneeThe Immune Response Corporation
InventorsJonas Salk, Dennis J. Carlo
Life of this patent
Estimating the term…
Abstract
The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce factors against progression of the infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.
Claims20
A method of stimulating the immune system of a human to produce antibodies, reduce viral burden or maintain CD4+ levels, comprising administering an immunogen comprising non-infectious intact HIV devoid of outer envelope proteins.
A method of stimulating the immune system of a human to produce antibodies, reduce viral burden or maintain CD4+ levels, comprising administering an immunogen comprising two or more HIV proteins, provided that none of said HIV proteins is an outer envelope protein.
A method of stimulating the immune system of a human to produce antibodies, reduce viral burden or maintain CD4+ levels, comprising administering an immunogen comprising non-infectious intact retrovirus devoid of outer envelope proteins.
A method of stimulating the immune system of a human to produce antibodies, reduce viral burden or maintain CD4+ levels, comprising administering an immunogen comprising two or more retroviral proteins, provided that none of said retroviral proteins is an outer envelope protein.
Dependencies are inferred from the claim text.